FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer

On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC).

Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news